VTRS / Viatris beats second-quarter revenue estimates, says divestiture plans on track

Viatris' (VTRS) Q3 results are likely to have been boosted by the momentum in its branded and generic businesses. more_horizontal

Viatris tried to invalidate three of the patents covering Novo Nordisk's Ozempic. The courts rebuffed two of those attempts, but the third will be eva more_horizontal

Viatris (VTRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat more_horizontal

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates. more_horizontal

Viatris Inc's lack of discernable catalysts and greater downside risk is likely to weigh on the company's share price, according to BofA Securities an more_horizontal

VTRS lost its Humira biosimilar through the divestiture of its biosimilar segment to Biocon, with the former similarly losing another growth prospects more_horizontal

Viatris is advancing in its plan to become leaner and pay off its debt. To do so, it's offloading a trio of non-core business segments. more_horizontal

Drugmaker Viatris said on Sunday that it has entered into agreements to divest its businesses, including the Women's Healthcare business and its Activ more_horizontal